Papers › FreeTumor: Large-Scale Generative Tumor Synthesis in Computed Tomography Images for...
FreeTumor: Large-Scale Generative Tumor Synthesis in Computed Tomography Images for Improving Tumor Recognition
Linshan Wu, Jiaxin Zhuang, Yanning Zhou, Sunan He, Jiabo Ma, Luyang Luo, Xi Wang, Xuefeng Ni, Xiaoling Zhong, Mingxiang Wu, Yinghua Zhao, Xiaohui Duan, Varut Vardhanabhuti, Pranav Rajpurkar, Hao Chen
Tumor is a leading cause of death worldwide, with an estimated 10 million deaths attributed to tumor-related diseases every year. AI-driven tumor recognition unlocks new possibilities for more precise and intelligent tumor screening and diagnosis. However, the progress is heavily hampered by the scarcity of annotated datasets, which demands extensive annotation efforts by radiologists. To tackle this challenge, we introduce FreeTumor, an innovative Generative AI (GAI) framework to enable large-scale tumor synthesis for mitigating data scarcity. Specifically, FreeTumor effectively leverages a combination of limited labeled data and large-scale unlabeled data for tumor synthesis training. Unleashing the power of large-scale data, FreeTumor is capable of synthesizing a large number of realistic tumors on images for augmenting training datasets. To this end, we create the largest training dataset for tumor synthesis and recognition by curating 161,310 publicly available Computed Tomography (CT) volumes from 33 sources, with only 2.3% containing annotated tumors. To validate the fidelity of synthetic tumors, we engaged 13 board-certified radiologists in a Visual Turing Test to discern between synthetic and real tumors. Rigorous clinician evaluation validates the high quality of our synthetic tumors, as they achieved only 51.1% sensitivity and 60.8% accuracy in distinguishing our synthetic tumors from real ones. Through high-quality tumor synthesis, FreeTumor scales up the recognition training datasets by over 40 times, showcasing a notable superiority over state-of-the-art AI methods including various synthesis methods and foundation models. These findings indicate promising prospects of FreeTumor in clinical applications, potentially advancing tumor treatments and improving the survival rates of patients.
Syntology This paper's arXiv id is not in Syntology's Atlas id list (549,449 ids, as this build read them; the read time is in the build record), so this page links to no Syntology page for it. The list is not the whole graph; Syntology's feed shows papers as they enter the graph.
Code
Repository list and official/mentioned flags are the archive's, frozen 2025-07-28. Reachability, where shown, is from one Syntology probe window (2026-09-16 to 2026-09-18); repositories not probed show nothing. GitHub stars are not tracked.
A paper named beside a repository with no sample linked to this paper is shown with that paper's own run record, not this paper's: “ran” means executed on a synthesized input, not that the code is correct, and “where Syntology's instrument failed” counts failures of Syntology's instrument, not of the code. Papers are listed in arXiv-id order, at most three per repository.
Code Syntology ran Syntology
Not run by Syntology. Nothing on this page verifies that the listed code works.
Tasks
Results from the paper archive 2025-07-28
No leaderboard rows for this paper in the archive.
Report a problem or propose a change · a person checks every report against the paper or source before anything changes; decisions are listed on /corrections